| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | DHSC referral received |
| Process | STA Standard |
| ID number | 6131 |
Provisional Schedule
| Expected publication | 20 December 2023 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
Stakeholders
| Companies sponsors | Boehringer Ingelheim (empagliflozin) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Diabetes UK |
| Kidney Care UK | |
| Kidney Research UK | |
| Professional groups | Royal College of Physicians |
| Society for DGH Nephrologists | |
| UK Kidney Association | |
| UK Renal Pharmacy Group | |
| Comparator companies | AstraZeneca (dapagliflozin) |
| Eisai Limited | |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 November 0003 - 01 December 2023 | Final draft guidance |
| 25 April 2023 | Invitation to participate |
| 02 November 2022 - 30 November 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 13 October 2022 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual